P61964 (WDR5_HUMAN) Homo sapiens (Human)

WD repeat-containing protein 5 UniProtKBInterProSTRINGInteractive Modelling

334 aa; Sequence (Fasta) 51 identical sequences

Sequence Features

Add
 107Important for interaction with histone H3
 133Important for interaction with histone H3
 263Important for interaction with histone H3
 322Important for interaction with histone H3
 208T -> M (de novo variant found in a patient with childhood apraxia of speech; unknown pathological significance) VAR_081531
 39-72WD40 repeat
IPR001680PF00400
 79-115WD40 repeat
IPR001680PF00400
 119-157WD40 repeat
IPR001680PF00400
 161-199WD40 repeat
IPR001680PF00400
 203-242WD40 repeat
IPR001680PF00400
 246-287WD40 repeat
IPR001680PF00400
 293-331WD40 repeat
IPR001680PF00400

Sequence Alignments

Experimental structures

DescriptionOligo-stateLigandsStructureRange
Modulating Protein-Protein Interactions with Visible Light Peptide Backbone Switches Heteromer
G2XKQ0;
K;NA;6iam29-334
Assess
WDR5 and Histone H3 Lysine 4 dimethyl complex at 2.1 angstrom Heteromer
P68431;
2cnx29-334
Assess
WDR5 in complex with influenza NS1 C-terminal tail Heteromer
P03495;
17×UNX;4o4530-334
Assess
X-ray structure of WDR5-MLL3 Win motif peptide binary complex Heteromer
Q8NEZ4;
4ery31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL2 Heteromer
O14686;
BTB;SO4;3uvk31-334
Assess
Crystal structure of the KANSL1-WDR5 complex. Heteromer
Q7Z3B3;
GOL;4cy131-334
Assess
X-ray structure of WDR5-SETd1a Win motif peptide binary complex Heteromer
O15047;
4ewr31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL4 Heteromer
Q9UMN6;
3uvm31-334
Assess
Crystal structure of human WDR5 in complex with monomethyl H3R2 peptide Heteromer
Q6NXT2;
GOL;SO4;6oi331-334
Assess
X-ray structure of WDR5-MLL1 Win motif peptide binary complex Heteromer
Q03164;
4esg31-334
Assess
Structure of WDR5 bound to MLL1 peptide Heteromer
Q03164;
SO4;3eg631-334
Assess
X-ray structure of WDR5-MLL4 Win motif peptide binary complex Heteromer
Q9UMN6;
4erz31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1A Heteromer
O15047;
3uvn31-334
Assess
X-ray structure of WDR5-SETd1b Win motif peptide binary complex Heteromer
Q9UPS6;
4es031-334
Assess
Crystal structure of WDR5 in complex with MYC MbIIIb peptide Heteromer
P01106;
TRS;EDO;4y7r31-334
Assess
WDR5 in complex with unmodified H3K4 peptide Heteromer
Q6P823;
2h9m31-334
Assess
X-ray structure of WDR5-MLL2 Win motif peptide binary complex Heteromer
O14686;
4erq31-334
Assess
WDR5 in complex with trimethylated H3K4 peptide Heteromer
Q6P823;
2h9p31-334
Assess
WDR5 in complex with monomethylated H3K4 peptide Heteromer
Q6P823;
2h9n31-334
Assess
Crystal structure of the KANSL1-WDR5-KANSL2 complex. Heteromer
Q7Z3B3; Q9H9L4;
4cy231-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1B Heteromer
Q9UPS6;
3uvo31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL3 Heteromer
Q8NEZ4;
3uvl31-334
Assess
WDR5 and unmodified Histone H3 complex at 2.25 angstrom Heteromer
P68431;
2co031-334
Assess
Structural and biochemical insights into MLL1 core complex assembly and regulation. Heteromer
Q03164; Q15291;
3p4f31-334
Assess
WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE RECRUITED TO NOVEL SITE Heteromer
P61965; Q8BX09;
GOL;2xl231-334
Assess
Crystal structure of WDR5-Mb(S4) monobody complex Heteromer
6byn31-334
Assess
Symmetric Dimethylation of H3 Arginine 2 is a Novel Histone Mark that Supports Euchromatin Maintena… Heteromer
P68431;
4a7j32-334
Assess
WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE AND HISTONE H3 PEPTIDE Heteromer
P61965; P68433; Q8BX09;
GOL;2xl332-334
Assess
Crystal structure of WDR5 in complex with the WIN peptide of PDPK1 Heteromer
O15530;
6wjq30-332
Assess
Cryo-EM structure of MLL1 core complex bound to the nucleosome Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9C005; Q9UBL3;
SAH;ZN;6pwv32-334
Assess
Cryo-EM structure of MLL1 in complex with RbBP5 and WDR5 bound to the nucleosome Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291;
SAH;ZN;6pww32-334
Assess
Structural basis of WDR5-MLL interaction Heteromer
Q03164;
SO4;3emh33-332
Assess
Cryo-EM structure of human MLL3-ubNCP complex (4.0 angstrom) Heteromer
P02281; P06897; P62799; P62979; P84233; Q15291; Q8NEZ4; Q9UBL3;
ZN;6kiw33-332
Assess
Cryo-EM structure of human MLL1-NCP complex, binding mode1 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3;
SAH;ZN;LYS;GLN;6kix33-332
Assess
Cryo-EM structure of human MLL1-NCP complex, binding mode2 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3;
SAH;ZN;6kiz33-332
Assess
Cryo-EM structure of human MLL1-ubNCP complex (3.2 angstrom) Heteromer
P02281; P06897; P62799; P62979; P84233; Q03164; Q15291; Q9UBL3;
SAH;ZN;LYS;GLN;6kiu33-332
Assess
Cryo-EM structure of human MLL1-ubNCP complex (4.0 angstrom) Heteromer
P02281; P06897; P62799; P62979; P84233; Q03164; Q15291; Q9UBL3;
SAH;ZN;6kiv33-332
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…homo-2-mer QF1;6uoz31-334
Assess
Characterization of Peptide Ligands Against WDR5 Isolated Using Phage Display Techniquehomo-2-mer 7dno31-334
Assess
Structure of wdr5monomer CL;2gnq11-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…monomer QBS;SO4;6ujh22-334
Assess
Discovery and Structure-Based optimization of potent and selective WDR5 inhibitors containing a dih…monomer Q41;6ucs23-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer Q0Y;6u6w24-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer Q1M;6u8b24-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer Q1J;6u8024-334
Assess
Crystal structure of human WDR5 in complex with compound 9emonomer 5MO;GOL;CL;EDO; 14×UNX;5eap24-334
Assess
WDR5delta23monomer SO4;2h9l24-334
Assess
Crystal structure of human WD repeat domain 5 with compound MM-401monomer 4gm924-334
Assess
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinitymonomer HLP;6e1z28-334
Assess
Crystal structure of human WD repeat domain 5 with compound MM-402monomer 4gmb28-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…monomer QBM;6ujl30-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer DMS;G2V;6dai30-334
Assess
Crystal structure of human WD REPEAT DOMAIN 5 in complex with 2-chloro-4-fluoro-3-methyl-N-[2-(4-me…monomer IA9;EDO; 24×UNX;4ia930-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…monomer QBP;6ujj30-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer G2D;6das30-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer NA;FZM;6d9x30-334
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer 2h6k30-334
Assess
WDR5 in complex with a WIN site inhibitormonomer HHM;SO4;DMS;6dya30-334
Assess
Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protei…monomer 2g9a29-333
Assess
WDR5 in complex with Myc site fragment inhibitormonomer Q8D;6uhz31-334
Assess
WDR5 in complex with Myc site fragment inhibitormonomer Q8G;6uhy31-334
Assess
Crystal structure of human WDR5 in complex with compound OICR-9429monomer 35Q;UNX;4ql131-334
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer 2h6n31-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…monomer Q8S;6uj431-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer Q0M;6u5y31-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer Q1P;Q1S;6u8l31-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer Q1G;6u8o31-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer G1Y;DMS;6dak31-334
Assess
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinitymonomer HLS;SO4;6e2231-334
Assess
WDR5 bound to inhibitor MM-589monomer 9BA;SO4;EDO;5vfc31-334
Assess
WDR5delta23 bound to (2-(3-phenylpropyl)-1H-imidazol-4-yl)methanolmonomer OGY;CL;6pg831-334
Assess
Crystal structure of human WDR5 in complex with symmetric dimethyl-L-argininemonomer SO4;GOL;2MR;6oi231-334
Assess
WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acetamidemonomer SO4;OH7;CL;6pg631-334
Assess
Crystal structure of human WDR5 in complex with monomethyl L-argininemonomer SO4;GOL;NMM;6oi131-334
Assess
WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)benzamidemonomer OH1;6pg931-334
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer 2h6831-334
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer Q0S;6u5m31-334
Assess
Crystal structure of human WDR5 in complex with compound 9omonomer 5MN;EDO; 11×UNX;5eam31-334
Assess
Crystal structure of WDR5, WD repeat domain 5 in complex with compound SGC-DS-MT-0345monomer 37F;CL;EDO;UNX;4qqe31-334
Assess
Crystal structure of human WDR5 in complex with compound 9dmonomer 5MQ;EDO;UNX;5ear31-334
Assess
Crystal structure of human WDR5 in complex with compound 9hmonomer 5ML;GOL;CL;EDO; 13×UNX;5eal31-334
Assess
Crystal structure of human WD repeat domain 5 with compoundmonomer 0BW;EDO;CL;SO4; 17×UNX;3ur431-334
Assess
Crystal structure of human WD repeat domain 5 with compoundmonomer NP7;EDO;UNX;3smr31-334
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer 2h6q31-334
Assess
Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protei…monomer 2g9930-333
Assess
WDR5 in Complex with Dimethylated H3K4 Peptidemonomer 2o9k31-334
Assess
WDR5 in complex with a WIN site inhibitormonomer HH7;DMS;SO4;6dy731-334
Assess
Crystal structure of human WDR5 in complex with L-argininemonomer ARG;SO4;GOL;6oi031-334
Assess
WDR5 in complex with MLL Win motif peptidomimeticmonomer 5sxm31-334
Assess
WDR5delta23 bound to (2-butyl-1H-imidazol-4-yl)methanolmonomer OHJ;6pg331-334
Assess
Crystal structure of WDR5 mutant (S62A)monomer 3mxx31-334
Assess
Crystal structure of WDR5 mutant (W330F)monomer 3n0d31-334
Assess
Crystal structure of WDR5 mutant (W330Y)monomer 3n0e31-334
Assess
Crystal structure of human WD repeat domain 5 with compound MM-102monomer 4gm831-334
Assess
Crystal structure of human WD repeat domain 5 with compound MM-101monomer 4gm331-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer HLM;6e1y32-334
Assess
Crystal of WDR5 (apo-form)monomer 2h1432-334
Assess
WDR5delta32 bound to peptidomimeticmonomer OK4;SO4;6pgd32-334
Assess
WDR5delta32 bound to N-(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acrylamidemonomer OJP;SO4;6pgf32-334
Assess
Crystal structure of WDR5/histone H3 complexmonomer 2h1332-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…monomer Q8M;6uik32-334
Assess
WDR5delta32 bound to (2-methyl-1H-imidazol-4-yl)methanolmonomer OHG;SO4;6pg432-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…monomer Q8P;6uif32-334
Assess
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinitymonomer HLJ;6e2332-334
Assess
Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3 based peptide mimeticmonomer 3psl32-334
Assess
WDR5delta32 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)-2-phenylacetamidemonomer OJG;SO4;6pgb32-334
Assess
WDR5delta32 bound to ethyl 3-(4-(hydroxymethyl)-1H-imidazol-2-yl)propanoatemonomer OJM;SO4;EDO;6pge32-334
Assess
WDR5delta32 bound to methyl benzyl(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamatemonomer SO4;OJJ;6pgc32-334
Assess
Crystal structure of human WDR5monomer 6ofz32-334
Assess
WDR5delta32 bound to benzyl (4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamatemonomer OHV;SO4;6pg532-334
Assess
WD repeat-containing protein 5 complexed with N-[(3,5-dimethoxyphenyl)methyl]-4'-fluoro-5-{[(2E)-2-…monomer Q6S;6ufx32-334
Assess
WDR5delta32 bound to methyl (4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamatemonomer OGM;SO4;6pga32-334
Assess
WDR5delta32 bound to (2-(3-methoxy-3-phenylpropyl)-1H-imidazol-4-yl)methanolmonomer OH4;PEG;6pg732-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer G2J;SO4;DMS;6dar31-332
Assess
Modulation of MLL1 Methyltransferase Activitymonomer 7DC;5m2333-332
Assess
Modulation of MLL1 Methyltransferase Activitymonomer 7DU;5m2533-332
Assess